Avience Biomedicals Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹59(28.37%)
Premium (ELP)
Market participation is actively sought for Avience Biomedicals Limited's's ongoing Initial Public Offering, which encompasses a total value of 14,53,800 Shares. The offering includes 14,53,800 Shares in fresh equity.
The currently applicable price range of ₹196 to ₹208 and minimum investment of 600 shares define participation criteria. The active subscription period represents a limited opportunity for investor engagement.
The application window will close on Jun 22, 2026, followed by allotment processing on Jun 23, 2026. Successful applicants will see their holdings listed for trading on Jun 25, 2026 at the NSE platform.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in June 2024, Avience Biomedicals Limited is an ISO-certified company engaged in the manufacturing, supply, and export of molecular diagnostic solutions for the biotechnology, genomics, and in-vitro diagnostics (IVD) sectors. The company offers a wide range of healthcare products, including rapid test kits, molecular diagnostic kits, biochemistry and hematology analyzers, medical devices, and diagnostic reagents. Its products serve pathology laboratories, hospitals, microbiology labs, and research centers in India and overseas. Along with manufacturing, the company also operates as a distributor and trader of medical equipment. Its manufacturing facility is located in Noida, Uttar Pradesh. As of January 31, 2026, Avience Biomedicals had 75 permanent employees and 33 contractual employees.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium is based on market buzz and online information. It should not be considered as the actual listing price or valuation. Always refer to the RHP and seek advice from a financial expert before making any investment decisions.
- Diversified Diagnostic Product Portfolio : Offers rapid test kits, analyzers, molecular diagnostics, and medical devices across multiple healthcare segments.
- Strong Distribution Network & Market Reach : Presence across India with growing international footprint supports business expansion.
- Quality-Focused Operations : ISO-certified processes and regulatory compliance enhance product reliability and customer trust.
- Limited Operating History : Recently incorporated company with a relatively short track record.
- Regulatory Compliance Risk : Medical devices and diagnostic products are subject to stringent approvals and regulations.
- Dependence on Healthcare Industry Demand : Growth depends on spending by hospitals, laboratories, and healthcare institutions.
- Mr. Dharam Deo Choudhary
- Mr. Ram Nagina Choudhary
- Mr. Janardan Pal
- Ms. Deepa Choudhary
Avience Biomedicals Limited
Skyline Financial Services Private Limited